Research programme: drug discovery - Boehringer Ingelheim/Deinove
Latest Information Update: 07 Feb 2019
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim; Morphochem AG
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Germany
- 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
- 04 Feb 2004 Preclinical trials in Undefined in Germany (unspecified route)